What changed
$VEEV — BUY 📊 | 6 MONTHS THESIS
🧭 Conviction: MED
🎯 FQ1 FY2027 (ends Apr) | reported Jun 03 | Rev $883M | EPS $2.24 vs $2.14 🟢 | Margin 30.9%
💡 Consensus expects slowing growth to ~12-13% as pharma IT budgets tighten, but Veeva's strategic positioning and AI-enabled products could drive sustained 15%+ growth and margin expansion, leading to multiple rerating.
📉 Reward/risk: 3.2:1
🏢 Business Quality: 8/10
📊 Valuation: cheap — trailing P/E 19.1x vs peer median ~25x; implied FCF yield ~4% with strong cash conversion; DCF with 15% growth yields intrinsic ~$220/share,...
🔮 Catalyst: Next quarterly earnings report (expected September 2026)
💰 Entry: $171.36, stop $155.0, target $224.0
⚖️ Buy VEEV: cheap at 19x P/E with 3.2x reward/risk; target $224 on multiple rerating as AI-driven life sciences demand surprises.